123 related articles for article (PubMed ID: 22100260)
1. The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics.
Rawson DJ; Ballard S; Barber C; Barker L; Beaumont K; Bunnage M; Cole S; Corless M; Denton S; Ellis D; Floc'h M; Foster L; Gosset J; Holmwood F; Lane C; Leahy D; Mathias J; Maw G; Million W; Poinsard C; Price J; Russel R; Street S; Watson L
Bioorg Med Chem; 2012 Jan; 20(1):498-509. PubMed ID: 22100260
[TBL] [Abstract][Full Text] [Related]
2. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Giuliano F; Ückert S; Maggi M; Birder L; Kissel J; Viktrup L
Eur Urol; 2013 Mar; 63(3):506-16. PubMed ID: 23018163
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
Wang C
Curr Opin Urol; 2010 Jan; 20(1):49-54. PubMed ID: 19887943
[TBL] [Abstract][Full Text] [Related]
5. Application of physiologically based pharmacokinetic modeling to understanding the clinical pharmacokinetics of UK-369,003.
Watson KJ; Davis J; Jones HM
Drug Metab Dispos; 2011 Jul; 39(7):1203-13. PubMed ID: 21451120
[TBL] [Abstract][Full Text] [Related]
6. [Phosphodiesterase type 5 inhibitors for lower urinary tract symptoms induced by benign prostatic hyperplasia: an update].
He PB; Zha PJ; Xu DP
Zhonghua Nan Ke Xue; 2014 Jul; 20(7):651-6. PubMed ID: 25095624
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
Sawant SD; Lakshma Reddy G; Dar MI; Srinivas M; Gupta G; Sahu PK; Mahajan P; Nargotra A; Singh S; Sharma SC; Tikoo M; Singh G; Vishwakarma RA; Syed SH
Bioorg Med Chem; 2015 May; 23(9):2121-8. PubMed ID: 25801159
[TBL] [Abstract][Full Text] [Related]
8. A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
Allerton CM; Barber CG; Beaumont KC; Brown DG; Cole SM; Ellis D; Lane CA; Maw GN; Mount NM; Rawson DJ; Robinson CM; Street SD; Summerhill NW
J Med Chem; 2006 Jun; 49(12):3581-94. PubMed ID: 16759100
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.
Wang G; Liu Z; Chen T; Wang Z; Yang H; Zheng M; Ren J; Tian G; Yang X; Li L; Li J; Suo J; Zhang R; Jiang X; Terrett NK; Shen J; Xu Y; Jiang H
J Med Chem; 2012 Dec; 55(23):10540-50. PubMed ID: 23137303
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms.
Reneerkens OA; Rutten K; Akkerman S; Blokland A; Shaffer CL; Menniti FS; Steinbusch HW; Prickaerts J
Neurobiol Learn Mem; 2012 May; 97(4):370-9. PubMed ID: 22426465
[TBL] [Abstract][Full Text] [Related]
12. Crystal forms of SK-3530.
Song HO; Sohn YT
Arch Pharm Res; 2010 Dec; 33(12):2033-6. PubMed ID: 21191770
[TBL] [Abstract][Full Text] [Related]
13. A chemical proteomics based enrichment technique targeting the interactome of the PDE5 inhibitor PF-4540124.
Dadvar P; O'Flaherty M; Scholten A; Rumpel K; Heck AJ
Mol Biosyst; 2009 May; 5(5):472-82. PubMed ID: 19381362
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
Tamimi NA; Mincik I; Haughie S; Lamb J; Crossland A; Ellis P
BJU Int; 2010 Sep; 106(5):674-80. PubMed ID: 20184577
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit.
Morelli A; Comeglio P; Filippi S; Sarchielli E; Vignozzi L; Maneschi E; Cellai I; Gacci M; Lenzi A; Vannelli GB; Maggi M
Prostate; 2013 Mar; 73(4):428-41. PubMed ID: 22996758
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Reddy GL; Dar MI; Hudwekar AD; Mahajan P; Nargotra A; Baba AM; Nandi U; Wazir P; Singh G; Vishwakarma RA; Syed SH; Sawant SD
Bioorg Chem; 2019 Aug; 89():103022. PubMed ID: 31181491
[TBL] [Abstract][Full Text] [Related]
17. Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5.
Gong X; Wang G; Ren J; Liu Z; Wang Z; Chen T; Yang X; Jiang X; Shen J; Jiang H; Aisa HA; Xu Y; Li J
Bioorg Med Chem Lett; 2013 Sep; 23(17):4944-7. PubMed ID: 23867165
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats.
Yoo HH; Kim NS; Im GJ; Kim DH
Acta Pharmacol Sin; 2007 Aug; 28(8):1247-53. PubMed ID: 17640490
[TBL] [Abstract][Full Text] [Related]
19. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Zhao C; Kim SH; Lee SW; Jeon JH; Kang KK; Choi SB; Park JK
BJU Int; 2011 Jun; 107(12):1943-7. PubMed ID: 21054754
[TBL] [Abstract][Full Text] [Related]
20. PDE5 inhibitors for LUTS.
Mouli S; McVary KT
Prostate Cancer Prostatic Dis; 2009; 12(4):316-24. PubMed ID: 19687801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
